Tetranectin mimetic peptide tnp and its application

A technology that mimics peptides and linkins, applied in the field of biomedicine, can solve the problems that the role has not been reported, and the function and mechanism of TN are not clear.
CN108948158BActive Publication Date: 2021-06-15HENAN UNIVERSITY
0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
HENAN UNIVERSITY
Publication Date
2021-06-15

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention relates to the technical field of biomedicine, in particular to tetranectin-mimicking peptide TNP and its application in treating diseases caused by the release of HMGB1 from vascular endothelial cells. The sequence of the acetylated tetranectin mimetic peptide at the nitrogen end is Ac‑QPDGGKTENCAVLSGAANGKWFDKRCRDK‑biotin. The acetylated tetranectin mimetic peptide TNP can effectively prevent the hydrolysis of TNP and prolong its half-life to improve the biological efficacy of the drug. TNP is in use When preparing drugs for the treatment of sepsis and other diseases, it can effectively inhibit the release of HMGB1 from vascular endothelial cells, reduce the concentration of extracellular HMGB1, and reduce the death rate of septic mice, and can almost completely block renal ischemia-reperfusion in mice. Changes in plasma urea nitrogen and creatinine can reduce renal tubular necrosis after ischemia, achieve the purpose of treating acute kidney injury, and provide a new way for the diagnosis and treatment of human diseases caused by the release of HMGB1 from vascular endothelial cells.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The invention relates to the technical field of biomedicine, and relates to a tetranectin-mimetic peptide TNP and its application, in particular to a tetranectin-mimetic peptide TNP and its application in the preparation of medicines for treating diseases caused by the release of HMGB1 from vascular endothelial cells. Background technique

[0002] Sepsis is multiorgan failure caused by an infection-triggered host response. There are about 30 million patients in the world every year, and the case fatality rate reaches 20-70%. Therefore, it was identified as a major threat to human health by the World Health Assembly in 2017.

[0003] Acute kidney injury (acute kidney injury, AKI) refers to the creatinine level in the patient's serum increases to 0.3 mg / 100 ml within 48 hours or increases by 50% within 7 days. AKI is a common disease in hospitalized patients, especially in intensive care units, with a mortality rate of about 18.9-46.5%. AKI has infect...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More